Business

Biotech, pharma, and money in science

Gilead Sciences
Biotech

Startup Goldfinch Bio signs $109 million deal with Gilead to develop treatments for kidney disease

By Jonathan Saltzman — Boston Globe

Spinraza injection
Biotech

Your guide to the mounting competition among new SMA drugs

By Damian Garde and Adam Feuerstein

Google logo
Health Tech

5 names to know at Google: the key players driving its health push

By Rebecca Robbins

Subsys 1600 mcg video
Business

Insys jurors horrified at use of rap video to push sales

By Maria Cramer — Boston Globe and Jonathan Saltzman — Boston Globe

Cytokinetics
Biotech

Cytokinetics pushes ahead with ALS drug despite negative clinical trial outcome

By Adam Feuerstein

Jackson Moore
Biotech

Scientists see hope in a rare disease drug Wall Street has all but written off

By Damian Garde

Facebook logos photo illo
Business

Facebook as ‘the alternative clinic visit’: A conversation with the social media giant’s cardiologist

By Rebecca Robbins

Rivers of funding
Biotech

Biotech runs on venture capital. But not all VC models are created equal

By Kate Sheridan

John N. Kapoor
Pharma

Fentanyl executive John Kapoor’s conviction is good news for holding corporations accountable

By Matthew Herper

John Kapoor
Business

All five defendants found guilty in Insys trial

By Maria Cramer — Boston Globe and Jonathan Saltzman — Boston Globe

Jessica Richman - uBiome
Business

UBiome co-founders are placed on leave amid FBI investigation into company

By Andrew Joseph

Biotech

5 questions for Gilead’s rookie CEO on his Wall Street debut

By Damian Garde

Erika Cheung and Tyler Shultz
Business

From protégée to whistleblower: A former Theranos scientist says Elizabeth Holmes should ‘come forward and apologize’

By Rick Berke

Microsoft logo
Health Tech

5 names to know: the team leading Microsoft’s march into health care

By Casey Ross

Oakland - marijuana plant
Health

Harvard, MIT share $9 million gift to study marijuana’s health effects

By Felice J. Freyer — Boston Globe

IV in the sky
Biotech

The bears and bulls are fighting over drug maker InflaRx. Here’s how to know who will come out on top

By Adam Feuerstein

Business

In case around microbiome startup UBiome, FBI has heard allegations involving improper billing codes and physician relationships

By Rebecca Robbins

John Kapoor
Business

After 11 days, still no verdict in trial of former Insys drug executives

By Jonathan Saltzman — Boston Globe and Maria Cramer — Boston Globe

Charlie Baker
Biotech

MassBio’s push to soften state drug-price legislation produces plenty of drama

By Jon Chesto — Boston Globe

Street lights
The Pharmalot View

If the states don’t treat pharma as a utility, it may be ‘lights out’ for too many patients

By Ed Silverman

Biotech

Biogen sees no need for big changes in wake of Alzheimer’s drug setback

By Adam Feuerstein

MORE Red Blood Cells
Biotech

BioMarin’s hemophilia gene therapy faces a crucial durability test. Here are 9 things to know

By Adam Feuerstein

Apple - top 5
Health Tech

5 names to know at Apple: the people leading its move into health care

By Rebecca Robbins

Scale
Biotech

Gelesis aims to crack the weight-loss market with its new capsule

By Jonathan Saltzman — Boston Globe

Biotech

With real estate deal, Sanofi Genzyme boosts its bottom line in hot market

By Tim Logan

Elizabeth Holmes Theranos
Business

Ex-Theranos CEO Elizabeth Holmes to return to court in July to set possible trial date

By Rebecca Robbins and Damian Garde

Biotech

How does Biogen move beyond its Alzheimer’s drug blowup? Listen for the clues

By Adam Feuerstein

Biotech

A biotech startup’s lofty goal: Kill cancer with pills that target RNA instead of proteins

By Adam Feuerstein

IBM logo
Exclusive

IBM halting sales of Watson AI tool for drug discovery amid sluggish growth

By Casey Ross

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy